Remove 2012 Remove Exercise Remove Innovation
article thumbnail

Bayer to Present New Investigational Heart Failure Data, Continued Portfolio Research in Chronic Kidney Disease at ACC.25

DAIC

25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies." Additional ACC.25

article thumbnail

Bayer to Present New Investigational Heart Failure Data, Continued Portfolio Research

DAIC

25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies." Additional ACC.25

article thumbnail

Drug regulation – How does it work?

Dr. Malcolm Kendrick

That rate hovered steady in 2009 and 2010, and then rose to about 70% in 2011, 2012, and 2013. This has become a massive and resource intensive exercise and involves many other different ‘agencies’ that need to be brought to heel. Here’s The Data To Prove It.’ This year’s approval rate?